NCT05800223View on ClinicalTrials.gov

Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Non-small Cell Lung Cancer Metastatic
Interventions
DRUG

Almonertinib

The dosage is 110 mg/day (2 tablets/day) orally once a day

RADIATION

SBRT

SRT, 27Gy-40Gy/3-5f

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Shanghai Cancer Hospital, China

OTHER